CA2094608A1 - Dna construct for providing rna therapy - Google Patents
Dna construct for providing rna therapyInfo
- Publication number
- CA2094608A1 CA2094608A1 CA002094608A CA2094608A CA2094608A1 CA 2094608 A1 CA2094608 A1 CA 2094608A1 CA 002094608 A CA002094608 A CA 002094608A CA 2094608 A CA2094608 A CA 2094608A CA 2094608 A1 CA2094608 A1 CA 2094608A1
- Authority
- CA
- Canada
- Prior art keywords
- rna
- dna
- dna construct
- construct
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A DNA construct capable of generating a relatively high copy number of therapeutic RNA molecules, including ribozymes and anti-sense RNAs, in target cells for effecting gene therapy. The construct and method of the invention are particularly useful in suppressing hapadnavirus infection and may be clinically effective in treating hepatitis B virus carriers.
Description
W092/06693 1 2 0 ~ 4 ~ ~ 8 PCTtUS91/07859 DNA CONSTRUCT FOR PROVIDING RNA T~ERAPY
Field of the Invention The present invention relates to the field of gene therapy and in particular to a novel D~A . .
construct capable of genera~ing therapeutic R~A
~` s molecules in target cells, and to the use of such ;~
. .
- constructs in suppressing hepadnavirus infection and in providing selected anti-sense RNA therapy to ~
~:~ patients who would be benefitted by such therapy. -10 Description of_the Prior Art ~
:.- ~
Recent advances in recombinant DNA technology have brought the substantial promise of gene therapy ~ nearer to realization. Techniques have now been -. 15 developed that enable introduction of genetic material ;-` into mammalian cells via viral particles functioning :-` in the ordinary course of inf.ection. See: e.~., D.
McCormick, Bio-Technoloqv, 3:689-93(1985).
~ Retroviru3es have been reporl:ed to be e~pecially .
^. 20 useful as vectors for accomp]Lishing gene insertion.
W. Ander~on, Science, 226:40:l-09(1984). This :~
. therapeutic approach typical:Ly involves introduction ~;. of the retroviral vector ex vivo into autolo~ous cells from the site at which the therapy is to be directed, ~ 25 followed by reimplantation of the cells~
:.~ An alternative strategy for gene therapy involves :
-~ the use of anti-sense RNA specifically to block the ;-i function of a gene. See: I. Herskowitz, Nature, : 329:219-22(1987): and M. Innoue, Gene, 72:25-34(1988).
30 It has also been proposed to use highly . sequence-specific endoribonucleases, commonly known as ;
: ribozymes, to achieve cleavage and inactivation of ~ gene transcripts in vivo. According to this strategy, .. assuming knowledge of the transcribed sequence of the:~
gene, it should be possible to target one or more .
`~ SUBSmUTE SHEET
,.. , ~
: ., ,, ., .. , , . , .. ... . .. . , , . . - -.- ...... . - -.. . ~- . , .. . . .. . .. , -, . . ....... . .. ... .. .. ... .. .. . . .
.:.: :: . .... :.,. . - . . . . . ` .. . ..
. ,..... . ~... ... ;. . .
.: , . - .
W092/06C93 2 a 9 ~ PCT/US91/07859 ribozymes against specific RNA transcripts, with expression of the ribozyme in vivo cleaving the transcript so as to inhibit expression of the corresponding gene. J. Haselo~f et al., Nature, 334:S85-9l(1988). It is possible to design specific ribozymes, by altering a portiQn-of its nucleotide sequence, to direct cleavage against a wide variety of target RNAs. Thus, ribozymes are capable of targeted destruction of specific cellular or viral RNAs.
; lO Attempts to date to introduce into cells foreign DNA encoding a ribozyme have resulted in relatively - ^
low copy numbers of the ribozyme, thus raising concern about the prospective clinical ~fficacy of this approach to gene therapy.
;
Summary of the Invention In accordance with the present invention, there is provided a unique DNA construct capable of generating in target cells thlerapeutic RNA molecules, including ribozymes and anti-sense RNA, in relatively high copy number of up to lO0,000 copies or higher.
The DNA construct of the invention comprises a first ;;
; DNA segment which enables the construct to autonomou~ly replicate in the form of a DNA molecule, a second DNA segment capable of generating the therapeutic RNA molecules and a third DNA segment .` which comprises the second DNA segment and which is capable of autonomously replicating in the form o' an RNA molecule in the target cells.
According to a preferred embodiment, the construct of the invention includes as the third ~NA
segment multiple copies of a specific RNA satellite agent, known as hepatitis D virus, which upon replication in target cells, forms both identical and complementary RNA sequences. Inserted into this third ... ~
~ i SUBSTITUTE HEET
:. "
.- `
: ~ : `. . ,. ,:
W~92/~693 2 0 9 ~ S ~ ~ PCT/US91/Q7859 DNA segment, comprising more than one copy of the hepatitis D virus genome is the second DNA segment which encodes ribozymes or anti-sense RNA molecules which are thus expressed in the target cells. The DNA
5 copy of the hepatitis D viral genome, including the ~ -ribozyme or anti-sense encoding insert, is - incorporated in a conventional cloning/expression ~éctor, preferably an 5V40 vector, to form a DNA
construct which is able to replicate autonomously in 10 the form of a DNA molecule, and leads to HDV RNA -~--transcripts which proceed with extensîve RNA-directed RNA replication. ~l -:' : !
In clinical applications of the construct of the invention, the ribozyme or anti-sense RNA encoded by ~`
the con~truct will be directed against the RNA
pregenome of hepatitis B virus. Admini~tration of the resultant construct, in the form of virions packaged in the protein coat of hepatitis B virus, is expected to effectively suppress hepatitis B virus infection in ~; 20 chronic carriers thereof. Of course, the present ~; invention has broader applicability, as it enables i` site specific delivery of other therapeutically effective RNAs, including other ribozymes and anti-sense RNA, as a means of providing RNA therapy.
Among the more notable advantages of the DNA
construct of the invention are its relative high copy `~
number, tissue specificity and self-limiting replication. -The DNA construct and method of treating -~
hepatitis B virus infection in accordance with this ~ invention should provide needed relief to the `r substantial number of HBV carriers, for whom there is ;
no satisfactory treatment currently available, and `~ thereby diminish their risk of developing liver cirrhosis and hepatocellular carcinoma.
.. , ~
: :-,:
SlJBSmUT SHEET
.. . .
.". ~ ~ ` - - `
. ~, .
,-.
, ` . . . .
.
. ` ~ .
: ` :. . , ~ , `, .: ` :.- ~` ........... . ` `
W092/0~93 2 09 4 ~ ~ 8 4 _ PCT/US91/07B59 Brie DescriPtion of the Drawings Referring to the accompanying drawings:
FIG. 1 is an illustration of the structural features of unit length circùlar genomic (Fig. lB) and 5 antigenomic (Fig. lC) HDV RNA and the m~NA (Fig. lA) involved in synthesis of the delta antigen, in which are represented a self-cleavage site (o), a ~olyadenyLation site (o), a polyadenylation signal (D) and, upstream of the latter signal, an ~pen reading frame (195 amino acids) for the delta antigen.
FIG. 2 is a representation of the predicted secondary structure of the catalytic loop of a ribozyme of 35 bases directed against the chloramphenicol acetyltransferase (CAT) gene, as encoded by the DNA construct of ~he invention, with the insertion occurring between bases 796 and 798 of the HDV-derived segments of the construct. The `~
asterisks (*) indicate potential base pairing; the arrow indicates the site of RNA cleavage on the CAT
gene. The 21-nucleotide uppe!r strand is designated Sequence I.D. No. 1, and the 48-nucleotide lower strand is designated Sequence I.D. No. 2.
FIG. 3 is an audioradiograph, resulting from northern blot analysis of RNA recovered from cells ~ 25 transfected with a DNA construct of the invention, i~ comprising two copies of an HDV genome modified in accordance with this invention to include the anti-CAT
ribozyme represented in Fig. 2; the audioradiograph shows that the HDV genome, as modified, was capable of replication in target cells tLane 2). The RNA ~
` undergoing analysis was recovered from transfected ~-; COS7 cells, comparing RNA from the same cells which -~ were transfected with a construct comprising three DNA copieS of wild-type HDV (Lane 1), a construct comprising two DNA copies of an HDV genome modified to include the anti-CAT ribozyme represented .,. '~.
$lJBS~TE SHEET
. .
.. . . . ..
::
W~92/06693 2 0 9 4 ~ ~ ~ PCT/US91/07859 in Fig. 2, a delta anti~en-expressing clone (Lane 3), and untransfected cells ~Lane 4; negative control). A
positive control, i.e. RNA from the liver of an ~-infected chimpanzee, and a molecular weight marker s phiX/HaeIII, are also shown (Lanes c and M, respectively). The arrow indicates the mobility of unit-length genomic HDV RNA.
FIG. 4 is an audioradiograph resulting from a CAT
mRNA assay via Sl nuclease, the mRNA was recovered from COS7 cells expressing CAT by activation of the CMV-IE promoter. Cells were transfected with (i) an HDV-containing plasmid vector pSVL, without the anti-CAT ribozyme insert (Lane 2), (ii) the same plasmid modified to include the anti-CAT ribozyme ~-r~presented in Fig. 2 (Lane 3) and (iii) a construct comprising wild-type HDV (Lane 43. Molecular weight -~
markers and an aliquot of undi~ested probe are al90 ~;
; . shown (Lanes M and p, respectively).
FIG. 5 is a representation of the anticipated secondary s~ructure of the catalytic loop of a ~ ribozy~e of 35 bases, which is expected to have -~ clinical application agains~ conserved portions on the genomes of three hepadnaviruses (WHV, GSMV and HBV), `'~ as encoded by a DNA construct of the invention, with the insertion occurring between bases 795 and 796.
~. The a~terisks (*) indicate potential base-pairing; the :; arrow indicates the site of RNA cleavage on the ',i hepadnavirus genome. The 20-nucleotide upper strand 1--is designated Sequence I.D. No. 4, and the 55-nucleotide lower strand is designated Sequence I.D.
No. 5. `~
Detailed Description The following words and phrases are defined for ~ ;~
.. 35 reference in the description of invention as follows:
: .
;............ ' ~,,,~, SUBSTITUTE SHEET ~
;
, `- ., -.. , . . . , .. - ~ - . . ` :
,,, , . ~ . - . . :.... . . .
WV92/~693 PCT/US9l/07859 2a9 ~8 - 6 - ;
1. Therapeutic RNA molecule -- an RNA molecule that can be us~d intracellularly for a therapeutic purpose. For example, an RNA molecule that comprises a ribozyme, as discussed abové, can be designed to bind and exert catalytic cleavage activity against a selected viral or cellular RNA. Additionally, an RNA
sequence designed to be the complement of a selected -:
: ~iral or cellular RNA can bind and inactivate that RNA
species. Both ribozymes and "anti sense" RNA
molecules can be of therapeutic value in the cell by inhibiting ~he expression of a detrimental gene product or by inhibiting the replication of a virus :~
which relies on the function of an RNA species.
Field of the Invention The present invention relates to the field of gene therapy and in particular to a novel D~A . .
construct capable of genera~ing therapeutic R~A
~` s molecules in target cells, and to the use of such ;~
. .
- constructs in suppressing hepadnavirus infection and in providing selected anti-sense RNA therapy to ~
~:~ patients who would be benefitted by such therapy. -10 Description of_the Prior Art ~
:.- ~
Recent advances in recombinant DNA technology have brought the substantial promise of gene therapy ~ nearer to realization. Techniques have now been -. 15 developed that enable introduction of genetic material ;-` into mammalian cells via viral particles functioning :-` in the ordinary course of inf.ection. See: e.~., D.
McCormick, Bio-Technoloqv, 3:689-93(1985).
~ Retroviru3es have been reporl:ed to be e~pecially .
^. 20 useful as vectors for accomp]Lishing gene insertion.
W. Ander~on, Science, 226:40:l-09(1984). This :~
. therapeutic approach typical:Ly involves introduction ~;. of the retroviral vector ex vivo into autolo~ous cells from the site at which the therapy is to be directed, ~ 25 followed by reimplantation of the cells~
:.~ An alternative strategy for gene therapy involves :
-~ the use of anti-sense RNA specifically to block the ;-i function of a gene. See: I. Herskowitz, Nature, : 329:219-22(1987): and M. Innoue, Gene, 72:25-34(1988).
30 It has also been proposed to use highly . sequence-specific endoribonucleases, commonly known as ;
: ribozymes, to achieve cleavage and inactivation of ~ gene transcripts in vivo. According to this strategy, .. assuming knowledge of the transcribed sequence of the:~
gene, it should be possible to target one or more .
`~ SUBSmUTE SHEET
,.. , ~
: ., ,, ., .. , , . , .. ... . .. . , , . . - -.- ...... . - -.. . ~- . , .. . . .. . .. , -, . . ....... . .. ... .. .. ... .. .. . . .
.:.: :: . .... :.,. . - . . . . . ` .. . ..
. ,..... . ~... ... ;. . .
.: , . - .
W092/06C93 2 a 9 ~ PCT/US91/07859 ribozymes against specific RNA transcripts, with expression of the ribozyme in vivo cleaving the transcript so as to inhibit expression of the corresponding gene. J. Haselo~f et al., Nature, 334:S85-9l(1988). It is possible to design specific ribozymes, by altering a portiQn-of its nucleotide sequence, to direct cleavage against a wide variety of target RNAs. Thus, ribozymes are capable of targeted destruction of specific cellular or viral RNAs.
; lO Attempts to date to introduce into cells foreign DNA encoding a ribozyme have resulted in relatively - ^
low copy numbers of the ribozyme, thus raising concern about the prospective clinical ~fficacy of this approach to gene therapy.
;
Summary of the Invention In accordance with the present invention, there is provided a unique DNA construct capable of generating in target cells thlerapeutic RNA molecules, including ribozymes and anti-sense RNA, in relatively high copy number of up to lO0,000 copies or higher.
The DNA construct of the invention comprises a first ;;
; DNA segment which enables the construct to autonomou~ly replicate in the form of a DNA molecule, a second DNA segment capable of generating the therapeutic RNA molecules and a third DNA segment .` which comprises the second DNA segment and which is capable of autonomously replicating in the form o' an RNA molecule in the target cells.
According to a preferred embodiment, the construct of the invention includes as the third ~NA
segment multiple copies of a specific RNA satellite agent, known as hepatitis D virus, which upon replication in target cells, forms both identical and complementary RNA sequences. Inserted into this third ... ~
~ i SUBSTITUTE HEET
:. "
.- `
: ~ : `. . ,. ,:
W~92/~693 2 0 9 ~ S ~ ~ PCT/US91/Q7859 DNA segment, comprising more than one copy of the hepatitis D virus genome is the second DNA segment which encodes ribozymes or anti-sense RNA molecules which are thus expressed in the target cells. The DNA
5 copy of the hepatitis D viral genome, including the ~ -ribozyme or anti-sense encoding insert, is - incorporated in a conventional cloning/expression ~éctor, preferably an 5V40 vector, to form a DNA
construct which is able to replicate autonomously in 10 the form of a DNA molecule, and leads to HDV RNA -~--transcripts which proceed with extensîve RNA-directed RNA replication. ~l -:' : !
In clinical applications of the construct of the invention, the ribozyme or anti-sense RNA encoded by ~`
the con~truct will be directed against the RNA
pregenome of hepatitis B virus. Admini~tration of the resultant construct, in the form of virions packaged in the protein coat of hepatitis B virus, is expected to effectively suppress hepatitis B virus infection in ~; 20 chronic carriers thereof. Of course, the present ~; invention has broader applicability, as it enables i` site specific delivery of other therapeutically effective RNAs, including other ribozymes and anti-sense RNA, as a means of providing RNA therapy.
Among the more notable advantages of the DNA
construct of the invention are its relative high copy `~
number, tissue specificity and self-limiting replication. -The DNA construct and method of treating -~
hepatitis B virus infection in accordance with this ~ invention should provide needed relief to the `r substantial number of HBV carriers, for whom there is ;
no satisfactory treatment currently available, and `~ thereby diminish their risk of developing liver cirrhosis and hepatocellular carcinoma.
.. , ~
: :-,:
SlJBSmUT SHEET
.. . .
.". ~ ~ ` - - `
. ~, .
,-.
, ` . . . .
.
. ` ~ .
: ` :. . , ~ , `, .: ` :.- ~` ........... . ` `
W092/0~93 2 09 4 ~ ~ 8 4 _ PCT/US91/07B59 Brie DescriPtion of the Drawings Referring to the accompanying drawings:
FIG. 1 is an illustration of the structural features of unit length circùlar genomic (Fig. lB) and 5 antigenomic (Fig. lC) HDV RNA and the m~NA (Fig. lA) involved in synthesis of the delta antigen, in which are represented a self-cleavage site (o), a ~olyadenyLation site (o), a polyadenylation signal (D) and, upstream of the latter signal, an ~pen reading frame (195 amino acids) for the delta antigen.
FIG. 2 is a representation of the predicted secondary structure of the catalytic loop of a ribozyme of 35 bases directed against the chloramphenicol acetyltransferase (CAT) gene, as encoded by the DNA construct of ~he invention, with the insertion occurring between bases 796 and 798 of the HDV-derived segments of the construct. The `~
asterisks (*) indicate potential base pairing; the arrow indicates the site of RNA cleavage on the CAT
gene. The 21-nucleotide uppe!r strand is designated Sequence I.D. No. 1, and the 48-nucleotide lower strand is designated Sequence I.D. No. 2.
FIG. 3 is an audioradiograph, resulting from northern blot analysis of RNA recovered from cells ~ 25 transfected with a DNA construct of the invention, i~ comprising two copies of an HDV genome modified in accordance with this invention to include the anti-CAT
ribozyme represented in Fig. 2; the audioradiograph shows that the HDV genome, as modified, was capable of replication in target cells tLane 2). The RNA ~
` undergoing analysis was recovered from transfected ~-; COS7 cells, comparing RNA from the same cells which -~ were transfected with a construct comprising three DNA copieS of wild-type HDV (Lane 1), a construct comprising two DNA copies of an HDV genome modified to include the anti-CAT ribozyme represented .,. '~.
$lJBS~TE SHEET
. .
.. . . . ..
::
W~92/06693 2 0 9 4 ~ ~ ~ PCT/US91/07859 in Fig. 2, a delta anti~en-expressing clone (Lane 3), and untransfected cells ~Lane 4; negative control). A
positive control, i.e. RNA from the liver of an ~-infected chimpanzee, and a molecular weight marker s phiX/HaeIII, are also shown (Lanes c and M, respectively). The arrow indicates the mobility of unit-length genomic HDV RNA.
FIG. 4 is an audioradiograph resulting from a CAT
mRNA assay via Sl nuclease, the mRNA was recovered from COS7 cells expressing CAT by activation of the CMV-IE promoter. Cells were transfected with (i) an HDV-containing plasmid vector pSVL, without the anti-CAT ribozyme insert (Lane 2), (ii) the same plasmid modified to include the anti-CAT ribozyme ~-r~presented in Fig. 2 (Lane 3) and (iii) a construct comprising wild-type HDV (Lane 43. Molecular weight -~
markers and an aliquot of undi~ested probe are al90 ~;
; . shown (Lanes M and p, respectively).
FIG. 5 is a representation of the anticipated secondary s~ructure of the catalytic loop of a ~ ribozy~e of 35 bases, which is expected to have -~ clinical application agains~ conserved portions on the genomes of three hepadnaviruses (WHV, GSMV and HBV), `'~ as encoded by a DNA construct of the invention, with the insertion occurring between bases 795 and 796.
~. The a~terisks (*) indicate potential base-pairing; the :; arrow indicates the site of RNA cleavage on the ',i hepadnavirus genome. The 20-nucleotide upper strand 1--is designated Sequence I.D. No. 4, and the 55-nucleotide lower strand is designated Sequence I.D.
No. 5. `~
Detailed Description The following words and phrases are defined for ~ ;~
.. 35 reference in the description of invention as follows:
: .
;............ ' ~,,,~, SUBSTITUTE SHEET ~
;
, `- ., -.. , . . . , .. - ~ - . . ` :
,,, , . ~ . - . . :.... . . .
WV92/~693 PCT/US9l/07859 2a9 ~8 - 6 - ;
1. Therapeutic RNA molecule -- an RNA molecule that can be us~d intracellularly for a therapeutic purpose. For example, an RNA molecule that comprises a ribozyme, as discussed abové, can be designed to bind and exert catalytic cleavage activity against a selected viral or cellular RNA. Additionally, an RNA
sequence designed to be the complement of a selected -:
: ~iral or cellular RNA can bind and inactivate that RNA
species. Both ribozymes and "anti sense" RNA
molecules can be of therapeutic value in the cell by inhibiting ~he expression of a detrimental gene product or by inhibiting the replication of a virus :~
which relies on the function of an RNA species.
2. Autonomous replication -- ~he replication of . 15 a DNA or RNA molecule which is not dependent on the :
~ replication of other DNA or RNA molecules within a . cell. Generally, DNA or RNA molecules may replicate ~ :
autonomously if they possess an origin of replication, ~. allowing cellular polymerases to recognize them as .. 20 "replicable" species.
. 3. Identical and complementary RNA -- identical RNA strands comprise identical nucleotide sequences, :
.~ while their complementary strands are related by means :~
of Watson-Crick base-pairing.
`" 25 4. Co~v number -- the multiplicity per cell of ~.
^ RNA strands containiny the therapeutic RNA.
-, , ~: The ~NA construct of the invention comprises ::
~ three segments. The first segment includes a means :: 30 for autonomous replication of the entire DNA construct :i as a DNA molecule in appropriate host cells. This :' segment may be selected from any number of vectors which possess an origin of replication operable in the ~-. selected host cell. Suitable vectors include, for ~
example, pBR322 plasmid derivatives to enable ::
.~ autonomous replication in E. coli, SV40-based plasmid ~ .
SU~STITUTE SHEET
.'. , - . . . ~ . :
W~92/~6693 ~ 0 9 4 6 ~ ~ PCT/US91/07859 vectors to allow autonomous replication in selected animal cells, or "combination" vectors which would enable the construct to replicate in more than one type of host cell. In a preferred embodiment, a `~
combination vector i5 used, namely, pSVL (Pharmacia), which carries pBR322 sequences as well as SV40 sequences, allowing the vector to be propagated in ~ither E. coli or in certain cultured animal cells (e.g. COS monkey cells).
The DNA construct of the in~ention also contains a segment which is capable of replication as RNA in a suitable target cell. In general, such segments can be obtained as cDNA copies of selected viral RNA ~-genomes containing an origin of replication. The ~-~- lS proce~s of obtaining cDNA copies from RNA through the use of reverse transcriptase is well known and commonly used by those skilled in the art.
An advantageous source of autonomously replicating RNA is the class of RNA virus-like agents known as "satellite RNAs." Hepatitis D virus is a member of this class of virus-like species. In a preferred embodiment, the hepatitis D virus genome is `;, obtained from infected woodchuck hepatocytes and reverse-transcribed into cDN,A molecules, which are then assembled to provide a cDNA copy of the full-length genome. The HDV cDNA is then inserted in~o the pSVL vector using conventional cloning techniques. One important feature of the construct of ' the invention is that two or more such HDV-derived cDNA inserts must be present in the construct in order to achieve the desired effect.
The construct, as described thus far, is capable - of autonomous replication as a DNA molecule in its entirety in selected host cells. In addition, the HDV-derived cDNA segments are capable of autonomous replication as RNA molecules in selected target cells.
. .
. . .
. SlJBSTlTUT S~EET
,.`
.. . . .. . . , -.. . ... .. .
.. . . . . . .
W092t~93 PCT/US91/~7~59 ~09 4~ ~ -- 8 --However, the construct is not of therapeutic utility until it is modified to include a DNA segment that will ultimately generate the therapeutic RNA molecule.
This segment must be inserted in the RNA-derived portions of the construct to enable replication of the therapeutic RNA molecule as an RNA species. It is ; important to select an insertion site in the ~- RNA-derived segment which does not disrupt any functional portion of that segment. In a preferred embodiment, the insertion is made between positions 795 and 798 in each of two woodchuck HDV-derived cDNA
inserts in the construct. This position i5 advantageous in that it avoids the portions of the HDV
genome involved in critical secondary structure formation, gene expression, and the origin of `
replication. The structure and organization of the HDV genome is shown in Fig. 1 A-C, along with the location of insertion of the DNA segment which encodes ` a therapeutic RNA molecule. The sequence and ; 20 organization of the woodchuck HDV genome is described ~` more fully in ~uo et al., J Virol. 62: 1855-61 (1988) and Taylor, Sem nars in Virologv 1: 135-41 (1990~.
The therapeutic RNA-generating DNA insert may comprise for example, sequences encoding a ribozyme or an "anti-sense" ~N~ molecule directed against a ~" specific RNA target. To design either type of insert, , the nucleotide sequence of the target RNA must be ~- known. A relevant structure of a ribozyme is that of Haseloff & Gerlach, Nature 334: 585-91 (1988). For a review, see Cech, J. Amer. Med. Assn. 260: 3030-34 (Nov. 25, 1988).
; Therapeutic RNA-generating sequences may be ; inserted into the RNA-derived portion of the construct `~
in several ways. A preferred embodiment involves polymerase chain reaction (PCR) amplification of an oligonucleotide encoding a ribozyme directed against a ,,.~ ~'.
SUBSTITUTE SHEET
., ~., ` . . . . . .
. ; ' . ~ . . `:
. . ` ,;.
- ., W092/0~93 2 0 9 4 6 D 8 PCT/US9~/07859 selected mRNA or viral RNA species. Specific examples include a ribozyme directed against mess~nger RNA
encoding chloramphenicol acetyltransferase (CAT) (Haseloff h Gerlach, Nature 334: 585-91, 1988), and a ribozyme targeted to disrupt hepatitis B pre-genomic RNA. The structures of these ribozymes are shown -schematically in Figures 2 (Sequence I.D. No. 2) and 5 (Sequence I.D. No. 4), respectively. A ribozyme directed against the pre-genomic RNA of hepatitis B
virus is contemplated to be of great utility in suppressing hepatitis B viral replication in infected cells.
To achieve insertion, the ribozyme-encoding oligonucleotide insert is flanked on either side by sequences complementary to the region surrounding position 795-798 of the woodchuck HDV genome. The oligonucleotide is hybridized to the construct, then ' subjected to PCR amplification by methods well known in the art. The r~sulting population is comprised -~
almost exclusively of constIucts containing the ~` oligonucleotide insert.
An alternative method ior inserting sequences into the construct of the invention involves introducing a restriction s:ite into an appropriate position on the RNA-derived segment by PC~-amplified oligonucleotide-directed mutagenesis as described above. Inserts encoding therapeutic RNA molecules can then be introduced into the construct by traditional recombinant DNA methods involving restriction cleavage and ligation.
When administered to target cells, the DNA
construct of the invention is capable of delivering ~ . .
RNA-replic~ble segments encoding therapeutic RNA
~; molecules. This is a distinct advantage over previous methods for delivering therapeutic RNA molecules because it enables the generation of a very high copy SUBSmUTE SHEET ~ :~
,~ ~`'' ` .-.- ~ . ~ .. . . ..
~ . , ., ~ . . ; .
, W0~2/0~93 ~ o 3 ~ ~ ~ 8 PCT/U~91/07859 ~ 10 --number of therapeutic RNA molecules in each target cell. As noted above, a therapeutic RNA molecule delivered at low copy number is unlikely to provide a clinically useful effect. In contrast, the construct ~ S of the invention, when administered to target cells, ; can produce up to 100,000 or more copies of the therapeutic RNA molecule per cell. A ribozyme thus generated is capable of having an appreciable inhibitory effect on RNA species to which it is targeted. This effect is demonstrated in greater detail in Example 3 below.
The means by which such a high copy number may be achieved by using the HDV-derived construct arises from the replicative cycle of hepatitis D virus, as shown in Figure 1, and described more fully by Taylor, Semin~rs in Virology 1: 13S-41 11990). When a DNA
c~nstruct comprising the HDV-derived cDNA segments is administered to a target cell, the HDV genomic RNA, -~ including the therapeutic RNA insert, is formed within the cell by means of transcription. The HDV genome then replicates by forming a complete anti-genomic complementary RNA sequence. Both the genomic and anti-genomic RNA sequences are capable of continued rounds of replication, forminy many copies of both HDV
genomes and anti-genomes. However, it has been shown that many-fold more HDV genomes are formed than are HDV anti-genomes. Thus, the high copy number of replicated genomes in a cell is comprised mostly of the RNA species which is identical to the HDV genome.
Since it is the genomic strand which has been designed `` to contain the therapeutic RNA molecule, a correspondingly high copy number of the therapeutic RNA is formed, resulting in a demonstrable and ~ clinically effective quantity of therapeutic RNA
--i 35 molecules in each target cell.
.; :
, ,; . . ~::
.
'. :
, - .. - . . . ~. . , .. ... ~ " . ,... , :, - :
.`;,. . ... ,...... . ~ .. , - ,. .... .
. . - .
, ~: , '' . ' ' ' ? ' -:.. . . . . . .
,: ,. , ... ,,,: . . . . .- . . . : . .: '. .. .; ~ , ~ . .: , 2~9~1~08 W092~93 PCT/US91/0~59 The desired effect of a therapeutic RNA, such as the ribazyme directed against CAT mRNA, has been demonstrated by transfecting cultured cells with a DNA
construct of the invention, as described in Example 3 below. However, the greater utility of this invention is contemplat.ed to be in the clinical application of said DNA constructs. The uni~ue aspects of the hépatitis D virus lifecycle will enable constructs of the invention to be delivered in vivo directly to hepatocytes. This is possible because hepatitis D
:- virus is not capable of pa~kaging and releasing itself from host cells. HDV relies on functions supplied by other hepadnaviruses to complete that portion of its lifecycle. For example, when hepatiti~ B virus (HBV) provides the necessary packaging functions r th~ HDV
` envelope wi~l contain the same targeting signals as -~
the HBV envelope, thus specifying its target cell ; range to hepatocytes.
Since it is possible to carry out these -HBV-dependent packaging steps in vitro, the DNA
construct of the invention may be used initially to transfect cultured cells containing the necessary HBV
helper functions. The HDV-derived segments of the construct, containing the insert encoding the therapeutic RNA, will be tran~cribed into HDV genomes and antigenomes and amplified to a high copy number, as described earlier. These genomes can then be - packaged and released as intact virions carrying HBV
' targeting signals. The virions, containing HDV
genomes with therapeutic RNA inserts, can then be administered in a suitable pharmaceutical preparation to patients infected with hepadnaviruses. The virions will target and infect hepatocytes, the site of pre-existing hepadnavirus infection. Within these target cells the HDV genomes will be capable of replication, producing hundreds of thousands of copies ,-:
` ` `. .: , .
, ~ , . " , ~ .
:;
. .
W092/OS693 2 ~ ~ PCT/US91/0~859 of the therapeutic RNA. If the therapeutic RNA is designed to be a ribozyme directed against pre-genomic or other HsV RNA species, the HBV life cycle will be interrupted, causing!s~ppression of HBV-induced disease symptoms.
The following examples are provided to describe the invention in further detail. These examples are ~ntended merely to illustrate and not to limit the ; lnvention. Unless otherwise specified, general cloning methods following procedures set forth in Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989).
.
lS Construction of a DNA vector containing two cDNA
copies of the woodchuck hepatitis D viral genome.
Clonin~ -The RNA from the liver of an HDV infected woodchuck was used to create a cDNA library in lambda gtll. Total RNA from the liver of an infected woodchuck was isolated by extraction with guanidine .:. .
isothiocyanate and purified by centrifugation to equilibrium in cesium chloride (Chirgwin et al., ` Biochemistr~ 18: 5294-99, 1979). The RNA was further purified by rate zonal centrifugation in a sucrose ` gradient to obtain a size class containing full length HDV RNA. Briefly, this RNA was converted with reverse transcriptase and random oligonucleotide primers (Taylor et al., Biochim. Biophys. Acta 442: 324-30, 1976) to double-stranded cDNA. After sizing, EcoRI
linker was added and the product was inserted at the EcoRI site of lambda gtll. The library of clones obtained was initially screened with the subgenomic -length delta clone pkDl (Denniston ~t al., Science 232: 873-75, 198b). After further rounds of ~-screening, selected clones were subjected to DNA -,; .
. .
SUBSmUTE SHEET
:. , . ' .. . .. . .. .... . .. . .. .... ...
.. . . . .. .. . . ' .
... . . . . :
;.: : .. : ;...... : , wos~/0~93 2 ~ 9 4 ~ ~ 8 PCT/US91/07~59 sequence analysis to determine the complete nucleotide sequence of the woodchuck HDV.
DNA Sequencinq and Analysis The nucleotide sequencing reactions were done by the dideoxy chain termination method of Sanger et al., Proc. Nat. Acad. Sci. USA 74: 5463-67 (1977), with ~;
modiEications by Zagursky et al., Gene Anal. Tech. 2: -~ 89-94 (1985) and Tabor et al., Proc. Nat. Acad. Sci.
- U5A 84: 4767-71 (1987). Areas of uncertainty were confirmed by use of the modified Maxam-Gilbert method (Bencini et al., Biotechniques Jan./Feb. 1984, pp 4-5).
Computer-bàsed analysis of the obtained sequence - information was carried out by using the Sequence `` Analysis Software Package of the University of - 15 Wisconsin Genetics Computer Group (Devereaux et al., Nuc. Acids Res. 12: 387-95, 1984).
Three of the selected clones were transferred to ` the plasmid pGem4Blue (Promega). Parts of these ins~rts were assembled onto a single plasmid, oriented relative to the EcoRI site at position 1427 of the 1679-base HDV genome, thereby constructing a ' full-length DNA copy of the HDV genome. Then by a strategy involving partial digestions and additional insertions, the total insert was raised to a trimer.
This trimer was excised with BamHI and PvuII and force-cloned into the vector pSVL (Pharmacia) that had been cut with BamHI and SmaI. The resulting construct ~' was designated pSVL[D3].
EXAMPLE 2 `
Modification of unit-length HDV sequences to provide segments encoding a ribozyme direc~ed against mRNA for chloramphenicol acetyltransferase (CAT).
Addition of sequences encoding an antl-CAT
ribozyme (Haselhoff ~ Gerlach, Nature 334: 585-91 (1988)) was accomplished by PCR-amplified " ~
SIJBSTITUTE SHEET
, ~ ~ . . .
` . .`
i . ` , `. , ... . .
.. . . .. .
.. ..... ,. - . . . ..
.. ; ..... , .. . ~ . `, : ............... : -. - . . ~` . .
. . . . . .. . . .
- -. ~ ..
. ~ . . . -W092/~93 2 09 ~a8 - 14 - PCTtUS91/078~g oliogn~Icleotide-directed mutagenesis of a non-essential portion of the HDV genome-derived segments of the constructs. Position 797 of the woodchuck ~IDV genome wàs selected for mutagenesis. An oligonucleotide, comprising the anti-CAT
ribozyme-encoding sequence flanked by sequences complementary to positions 789-796 and 798-802 of the HDV genome was synthesized using phosphoramidite c~emistry (Sequence I.D. No. 2). A unit-length sequence was modified in this way, using PCR, with enzymes and procedures from Perkin-Elmer Co. The ;~ sequence was cloned, raised to a dimer, then transferred to pSVL and designated pSVL[D2-anti CAT].
lS EXAMPrE 3 :
^ Transfection of target cells with a construct of the invention and replication therefrom of HDV genomes ` containing therapeutic RNA molecules.
Trans~ection As described in Examples 1 and 2 above, a dimer X of the woodchuck HDV genomic sequence, each monomer containing a ribozyme insert, was assembled in the SV40-based vector pSVL. The construct was such that the RNA transcription, controlled by the Sv40 late promotor, produced transcripts of genomic HDV RNA.
This plasmid, designated pSVLlD2-anti CATI; was I transfected into a monkey kidney cell line, COS7, i originally isolated by Gluzman, Cell 23: 175-82 ~ :
(1981).
; 30 The DEAE-dextran transfection procedure was used as described by Cullen, Meth. Enz. 152: 684-704 (1987).
The procedure was scaled down to us~ 1~0,000 cells in a 16 mm diameter well, and to apply only I20 ng DNA in ~ -50 uL per well. After transfection the media was changed every second day until harvest. The cells were washed and removed by scraping, then the RNA
'"'.' ''"
. :
SUBSmUT~ SHEET
.
2 a 9 ~
W092/~93 PCT/US91/07859 contained therein was extracted and subjected to Northern blot analysis, as described by Chen et al., Proc. Nat. Acad. Sci. USA 83: 8774-78 (1988).
Northern analysis of transfected cells verified -that the therapeutic RNA-containing HDV genomes of the construct were able to undergo normal rounds of replication as RNA molecuLes, as shown and described sn Fig. 3 of the drawings. Additionally, HDV
rëplication was sufficiently high to yield effective quantities of the anti-CAT ribo2yme contained therein, as described in Fig. 4. As shown, target cells expressing CAT were subjected to transfection by constructs containing either (1) pSVL alone, (2) a construct of the invention (pSVLlD2-anti CAT]) or (3) a construct containing a trimer of HDV-derived cDNAs, but without a ribozyme insert. Transfection with the ~ construct of the invention r~esulted in a 3- to 5-fold .-"~ inhibition of C~T activity in said target cells.
The present invention is not limited to the embodiments specifically described and exemplified above, but is capable of variation and modification `~ without departure from the scope of the appended claims.
~ ;
, . "' ~
.
.. , :
~
;~:
... :
~ . SlJBSTlTUTE SHEET : :
,., ~.
,., . ` ~ .... ,, . .. , ,. .. ` .
: ` . . ` , ` , ` , . . . , ` ' . . , ~ ` . ,, . - ` .
.` , ... - ; . .. ~ - . ..
. . . . . . .
~ replication of other DNA or RNA molecules within a . cell. Generally, DNA or RNA molecules may replicate ~ :
autonomously if they possess an origin of replication, ~. allowing cellular polymerases to recognize them as .. 20 "replicable" species.
. 3. Identical and complementary RNA -- identical RNA strands comprise identical nucleotide sequences, :
.~ while their complementary strands are related by means :~
of Watson-Crick base-pairing.
`" 25 4. Co~v number -- the multiplicity per cell of ~.
^ RNA strands containiny the therapeutic RNA.
-, , ~: The ~NA construct of the invention comprises ::
~ three segments. The first segment includes a means :: 30 for autonomous replication of the entire DNA construct :i as a DNA molecule in appropriate host cells. This :' segment may be selected from any number of vectors which possess an origin of replication operable in the ~-. selected host cell. Suitable vectors include, for ~
example, pBR322 plasmid derivatives to enable ::
.~ autonomous replication in E. coli, SV40-based plasmid ~ .
SU~STITUTE SHEET
.'. , - . . . ~ . :
W~92/~6693 ~ 0 9 4 6 ~ ~ PCT/US91/07859 vectors to allow autonomous replication in selected animal cells, or "combination" vectors which would enable the construct to replicate in more than one type of host cell. In a preferred embodiment, a `~
combination vector i5 used, namely, pSVL (Pharmacia), which carries pBR322 sequences as well as SV40 sequences, allowing the vector to be propagated in ~ither E. coli or in certain cultured animal cells (e.g. COS monkey cells).
The DNA construct of the in~ention also contains a segment which is capable of replication as RNA in a suitable target cell. In general, such segments can be obtained as cDNA copies of selected viral RNA ~-genomes containing an origin of replication. The ~-~- lS proce~s of obtaining cDNA copies from RNA through the use of reverse transcriptase is well known and commonly used by those skilled in the art.
An advantageous source of autonomously replicating RNA is the class of RNA virus-like agents known as "satellite RNAs." Hepatitis D virus is a member of this class of virus-like species. In a preferred embodiment, the hepatitis D virus genome is `;, obtained from infected woodchuck hepatocytes and reverse-transcribed into cDN,A molecules, which are then assembled to provide a cDNA copy of the full-length genome. The HDV cDNA is then inserted in~o the pSVL vector using conventional cloning techniques. One important feature of the construct of ' the invention is that two or more such HDV-derived cDNA inserts must be present in the construct in order to achieve the desired effect.
The construct, as described thus far, is capable - of autonomous replication as a DNA molecule in its entirety in selected host cells. In addition, the HDV-derived cDNA segments are capable of autonomous replication as RNA molecules in selected target cells.
. .
. . .
. SlJBSTlTUT S~EET
,.`
.. . . .. . . , -.. . ... .. .
.. . . . . . .
W092t~93 PCT/US91/~7~59 ~09 4~ ~ -- 8 --However, the construct is not of therapeutic utility until it is modified to include a DNA segment that will ultimately generate the therapeutic RNA molecule.
This segment must be inserted in the RNA-derived portions of the construct to enable replication of the therapeutic RNA molecule as an RNA species. It is ; important to select an insertion site in the ~- RNA-derived segment which does not disrupt any functional portion of that segment. In a preferred embodiment, the insertion is made between positions 795 and 798 in each of two woodchuck HDV-derived cDNA
inserts in the construct. This position i5 advantageous in that it avoids the portions of the HDV
genome involved in critical secondary structure formation, gene expression, and the origin of `
replication. The structure and organization of the HDV genome is shown in Fig. 1 A-C, along with the location of insertion of the DNA segment which encodes ` a therapeutic RNA molecule. The sequence and ; 20 organization of the woodchuck HDV genome is described ~` more fully in ~uo et al., J Virol. 62: 1855-61 (1988) and Taylor, Sem nars in Virologv 1: 135-41 (1990~.
The therapeutic RNA-generating DNA insert may comprise for example, sequences encoding a ribozyme or an "anti-sense" ~N~ molecule directed against a ~" specific RNA target. To design either type of insert, , the nucleotide sequence of the target RNA must be ~- known. A relevant structure of a ribozyme is that of Haseloff & Gerlach, Nature 334: 585-91 (1988). For a review, see Cech, J. Amer. Med. Assn. 260: 3030-34 (Nov. 25, 1988).
; Therapeutic RNA-generating sequences may be ; inserted into the RNA-derived portion of the construct `~
in several ways. A preferred embodiment involves polymerase chain reaction (PCR) amplification of an oligonucleotide encoding a ribozyme directed against a ,,.~ ~'.
SUBSTITUTE SHEET
., ~., ` . . . . . .
. ; ' . ~ . . `:
. . ` ,;.
- ., W092/0~93 2 0 9 4 6 D 8 PCT/US9~/07859 selected mRNA or viral RNA species. Specific examples include a ribozyme directed against mess~nger RNA
encoding chloramphenicol acetyltransferase (CAT) (Haseloff h Gerlach, Nature 334: 585-91, 1988), and a ribozyme targeted to disrupt hepatitis B pre-genomic RNA. The structures of these ribozymes are shown -schematically in Figures 2 (Sequence I.D. No. 2) and 5 (Sequence I.D. No. 4), respectively. A ribozyme directed against the pre-genomic RNA of hepatitis B
virus is contemplated to be of great utility in suppressing hepatitis B viral replication in infected cells.
To achieve insertion, the ribozyme-encoding oligonucleotide insert is flanked on either side by sequences complementary to the region surrounding position 795-798 of the woodchuck HDV genome. The oligonucleotide is hybridized to the construct, then ' subjected to PCR amplification by methods well known in the art. The r~sulting population is comprised -~
almost exclusively of constIucts containing the ~` oligonucleotide insert.
An alternative method ior inserting sequences into the construct of the invention involves introducing a restriction s:ite into an appropriate position on the RNA-derived segment by PC~-amplified oligonucleotide-directed mutagenesis as described above. Inserts encoding therapeutic RNA molecules can then be introduced into the construct by traditional recombinant DNA methods involving restriction cleavage and ligation.
When administered to target cells, the DNA
construct of the invention is capable of delivering ~ . .
RNA-replic~ble segments encoding therapeutic RNA
~; molecules. This is a distinct advantage over previous methods for delivering therapeutic RNA molecules because it enables the generation of a very high copy SUBSmUTE SHEET ~ :~
,~ ~`'' ` .-.- ~ . ~ .. . . ..
~ . , ., ~ . . ; .
, W0~2/0~93 ~ o 3 ~ ~ ~ 8 PCT/U~91/07859 ~ 10 --number of therapeutic RNA molecules in each target cell. As noted above, a therapeutic RNA molecule delivered at low copy number is unlikely to provide a clinically useful effect. In contrast, the construct ~ S of the invention, when administered to target cells, ; can produce up to 100,000 or more copies of the therapeutic RNA molecule per cell. A ribozyme thus generated is capable of having an appreciable inhibitory effect on RNA species to which it is targeted. This effect is demonstrated in greater detail in Example 3 below.
The means by which such a high copy number may be achieved by using the HDV-derived construct arises from the replicative cycle of hepatitis D virus, as shown in Figure 1, and described more fully by Taylor, Semin~rs in Virology 1: 13S-41 11990). When a DNA
c~nstruct comprising the HDV-derived cDNA segments is administered to a target cell, the HDV genomic RNA, -~ including the therapeutic RNA insert, is formed within the cell by means of transcription. The HDV genome then replicates by forming a complete anti-genomic complementary RNA sequence. Both the genomic and anti-genomic RNA sequences are capable of continued rounds of replication, forminy many copies of both HDV
genomes and anti-genomes. However, it has been shown that many-fold more HDV genomes are formed than are HDV anti-genomes. Thus, the high copy number of replicated genomes in a cell is comprised mostly of the RNA species which is identical to the HDV genome.
Since it is the genomic strand which has been designed `` to contain the therapeutic RNA molecule, a correspondingly high copy number of the therapeutic RNA is formed, resulting in a demonstrable and ~ clinically effective quantity of therapeutic RNA
--i 35 molecules in each target cell.
.; :
, ,; . . ~::
.
'. :
, - .. - . . . ~. . , .. ... ~ " . ,... , :, - :
.`;,. . ... ,...... . ~ .. , - ,. .... .
. . - .
, ~: , '' . ' ' ' ? ' -:.. . . . . . .
,: ,. , ... ,,,: . . . . .- . . . : . .: '. .. .; ~ , ~ . .: , 2~9~1~08 W092~93 PCT/US91/0~59 The desired effect of a therapeutic RNA, such as the ribazyme directed against CAT mRNA, has been demonstrated by transfecting cultured cells with a DNA
construct of the invention, as described in Example 3 below. However, the greater utility of this invention is contemplat.ed to be in the clinical application of said DNA constructs. The uni~ue aspects of the hépatitis D virus lifecycle will enable constructs of the invention to be delivered in vivo directly to hepatocytes. This is possible because hepatitis D
:- virus is not capable of pa~kaging and releasing itself from host cells. HDV relies on functions supplied by other hepadnaviruses to complete that portion of its lifecycle. For example, when hepatiti~ B virus (HBV) provides the necessary packaging functions r th~ HDV
` envelope wi~l contain the same targeting signals as -~
the HBV envelope, thus specifying its target cell ; range to hepatocytes.
Since it is possible to carry out these -HBV-dependent packaging steps in vitro, the DNA
construct of the invention may be used initially to transfect cultured cells containing the necessary HBV
helper functions. The HDV-derived segments of the construct, containing the insert encoding the therapeutic RNA, will be tran~cribed into HDV genomes and antigenomes and amplified to a high copy number, as described earlier. These genomes can then be - packaged and released as intact virions carrying HBV
' targeting signals. The virions, containing HDV
genomes with therapeutic RNA inserts, can then be administered in a suitable pharmaceutical preparation to patients infected with hepadnaviruses. The virions will target and infect hepatocytes, the site of pre-existing hepadnavirus infection. Within these target cells the HDV genomes will be capable of replication, producing hundreds of thousands of copies ,-:
` ` `. .: , .
, ~ , . " , ~ .
:;
. .
W092/OS693 2 ~ ~ PCT/US91/0~859 of the therapeutic RNA. If the therapeutic RNA is designed to be a ribozyme directed against pre-genomic or other HsV RNA species, the HBV life cycle will be interrupted, causing!s~ppression of HBV-induced disease symptoms.
The following examples are provided to describe the invention in further detail. These examples are ~ntended merely to illustrate and not to limit the ; lnvention. Unless otherwise specified, general cloning methods following procedures set forth in Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory (1989).
.
lS Construction of a DNA vector containing two cDNA
copies of the woodchuck hepatitis D viral genome.
Clonin~ -The RNA from the liver of an HDV infected woodchuck was used to create a cDNA library in lambda gtll. Total RNA from the liver of an infected woodchuck was isolated by extraction with guanidine .:. .
isothiocyanate and purified by centrifugation to equilibrium in cesium chloride (Chirgwin et al., ` Biochemistr~ 18: 5294-99, 1979). The RNA was further purified by rate zonal centrifugation in a sucrose ` gradient to obtain a size class containing full length HDV RNA. Briefly, this RNA was converted with reverse transcriptase and random oligonucleotide primers (Taylor et al., Biochim. Biophys. Acta 442: 324-30, 1976) to double-stranded cDNA. After sizing, EcoRI
linker was added and the product was inserted at the EcoRI site of lambda gtll. The library of clones obtained was initially screened with the subgenomic -length delta clone pkDl (Denniston ~t al., Science 232: 873-75, 198b). After further rounds of ~-screening, selected clones were subjected to DNA -,; .
. .
SUBSmUTE SHEET
:. , . ' .. . .. . .. .... . .. . .. .... ...
.. . . . .. .. . . ' .
... . . . . :
;.: : .. : ;...... : , wos~/0~93 2 ~ 9 4 ~ ~ 8 PCT/US91/07~59 sequence analysis to determine the complete nucleotide sequence of the woodchuck HDV.
DNA Sequencinq and Analysis The nucleotide sequencing reactions were done by the dideoxy chain termination method of Sanger et al., Proc. Nat. Acad. Sci. USA 74: 5463-67 (1977), with ~;
modiEications by Zagursky et al., Gene Anal. Tech. 2: -~ 89-94 (1985) and Tabor et al., Proc. Nat. Acad. Sci.
- U5A 84: 4767-71 (1987). Areas of uncertainty were confirmed by use of the modified Maxam-Gilbert method (Bencini et al., Biotechniques Jan./Feb. 1984, pp 4-5).
Computer-bàsed analysis of the obtained sequence - information was carried out by using the Sequence `` Analysis Software Package of the University of - 15 Wisconsin Genetics Computer Group (Devereaux et al., Nuc. Acids Res. 12: 387-95, 1984).
Three of the selected clones were transferred to ` the plasmid pGem4Blue (Promega). Parts of these ins~rts were assembled onto a single plasmid, oriented relative to the EcoRI site at position 1427 of the 1679-base HDV genome, thereby constructing a ' full-length DNA copy of the HDV genome. Then by a strategy involving partial digestions and additional insertions, the total insert was raised to a trimer.
This trimer was excised with BamHI and PvuII and force-cloned into the vector pSVL (Pharmacia) that had been cut with BamHI and SmaI. The resulting construct ~' was designated pSVL[D3].
EXAMPLE 2 `
Modification of unit-length HDV sequences to provide segments encoding a ribozyme direc~ed against mRNA for chloramphenicol acetyltransferase (CAT).
Addition of sequences encoding an antl-CAT
ribozyme (Haselhoff ~ Gerlach, Nature 334: 585-91 (1988)) was accomplished by PCR-amplified " ~
SIJBSTITUTE SHEET
, ~ ~ . . .
` . .`
i . ` , `. , ... . .
.. . . .. .
.. ..... ,. - . . . ..
.. ; ..... , .. . ~ . `, : ............... : -. - . . ~` . .
. . . . . .. . . .
- -. ~ ..
. ~ . . . -W092/~93 2 09 ~a8 - 14 - PCTtUS91/078~g oliogn~Icleotide-directed mutagenesis of a non-essential portion of the HDV genome-derived segments of the constructs. Position 797 of the woodchuck ~IDV genome wàs selected for mutagenesis. An oligonucleotide, comprising the anti-CAT
ribozyme-encoding sequence flanked by sequences complementary to positions 789-796 and 798-802 of the HDV genome was synthesized using phosphoramidite c~emistry (Sequence I.D. No. 2). A unit-length sequence was modified in this way, using PCR, with enzymes and procedures from Perkin-Elmer Co. The ;~ sequence was cloned, raised to a dimer, then transferred to pSVL and designated pSVL[D2-anti CAT].
lS EXAMPrE 3 :
^ Transfection of target cells with a construct of the invention and replication therefrom of HDV genomes ` containing therapeutic RNA molecules.
Trans~ection As described in Examples 1 and 2 above, a dimer X of the woodchuck HDV genomic sequence, each monomer containing a ribozyme insert, was assembled in the SV40-based vector pSVL. The construct was such that the RNA transcription, controlled by the Sv40 late promotor, produced transcripts of genomic HDV RNA.
This plasmid, designated pSVLlD2-anti CATI; was I transfected into a monkey kidney cell line, COS7, i originally isolated by Gluzman, Cell 23: 175-82 ~ :
(1981).
; 30 The DEAE-dextran transfection procedure was used as described by Cullen, Meth. Enz. 152: 684-704 (1987).
The procedure was scaled down to us~ 1~0,000 cells in a 16 mm diameter well, and to apply only I20 ng DNA in ~ -50 uL per well. After transfection the media was changed every second day until harvest. The cells were washed and removed by scraping, then the RNA
'"'.' ''"
. :
SUBSmUT~ SHEET
.
2 a 9 ~
W092/~93 PCT/US91/07859 contained therein was extracted and subjected to Northern blot analysis, as described by Chen et al., Proc. Nat. Acad. Sci. USA 83: 8774-78 (1988).
Northern analysis of transfected cells verified -that the therapeutic RNA-containing HDV genomes of the construct were able to undergo normal rounds of replication as RNA molecuLes, as shown and described sn Fig. 3 of the drawings. Additionally, HDV
rëplication was sufficiently high to yield effective quantities of the anti-CAT ribo2yme contained therein, as described in Fig. 4. As shown, target cells expressing CAT were subjected to transfection by constructs containing either (1) pSVL alone, (2) a construct of the invention (pSVLlD2-anti CAT]) or (3) a construct containing a trimer of HDV-derived cDNAs, but without a ribozyme insert. Transfection with the ~ construct of the invention r~esulted in a 3- to 5-fold .-"~ inhibition of C~T activity in said target cells.
The present invention is not limited to the embodiments specifically described and exemplified above, but is capable of variation and modification `~ without departure from the scope of the appended claims.
~ ;
, . "' ~
.
.. , :
~
;~:
... :
~ . SlJBSTlTUTE SHEET : :
,., ~.
,., . ` ~ .... ,, . .. , ,. .. ` .
: ` . . ` , ` , ` , . . . , ` ' . . , ~ ` . ,, . - ` .
.` , ... - ; . .. ~ - . ..
. . . . . . .
Claims (23)
1. A DNA construct for generating therapeutic RNA molecules in target cells, said construct comprising:
i) a first DNA segment which enables said construct to autonomously replicate in the form of a DNA molecule;
ii) a second DNA segment capable of generating said therapeutic RNA molecule; and iii) a third DNA segment which comprises said second DNA segment, and which is capable of autonomously replicating in the form of an RNA
molecule in said target cells.
i) a first DNA segment which enables said construct to autonomously replicate in the form of a DNA molecule;
ii) a second DNA segment capable of generating said therapeutic RNA molecule; and iii) a third DNA segment which comprises said second DNA segment, and which is capable of autonomously replicating in the form of an RNA
molecule in said target cells.
2. The DNA construct of claim 1, wherein said first DNA segment is a vector derived from an animal virus.
3. The DNA construct of claim 2, wherein the animal virus DNA vector is SV40.
4. The DNA construct of claim 1, wherein said first segment is capable of replicating as DNA in animal cells and in bacterial cells.
5. The DNA construct of claim 4, wherein said first segment is the vector pSVL.
6. The DNA construct of claim 1 wherein replication of said third DNA segment in target cells results in the formation of identical and complementary RNA sequences.
7. The DNA construct of claim 1, wherein said third DNA segment comprises multiple copies of a genome derivable from an RNA satellite agent.
8. The DNA construct of claim 6, wherein said RNA satellite agent is Hepatitis D Virus.
9. The DNA construct of claim 8, wherein said second DNA segment is positioned so as not to disrupt essential functional portions of said third DNA segment.
10. The DNA construct of claim 9, wherein said first segment comprises pSVL, said third segment comprises two DNA copies of the genome of Hepatitis D
virus, and said second segment is positioned between nucleotides 795 and 798 on each copy of said HDV
genome.
virus, and said second segment is positioned between nucleotides 795 and 798 on each copy of said HDV
genome.
11. The DNA construct of claim 1, wherein said therapeutic RNA molecule generated by said second DNA segment is a ribozyme.
12. The DNA construct of claim 11, wherein said ribozyme is directed against a viral RNA species.
13. The DNA construct of claim 11, wherein said ribozyme is directed against hepadnavirus pre-genomic RNA.
14. The DNA construct of claim 13, wherein said hepadnavirus is Hepatitis B virus.
15. The DNA construct of claim 11, wherein said ribozyme is directed against a cellular RNA
species.
species.
16. The DNA construct of claim 1, wherein the therapeutic RNA molecule generated by said second DNA segment is an anti-sense RNA molecule.
17. The DNA construct of claim 16, wherein said anti-sense RNA molecule is directed against a viral RNA species.
18. The DNA construct of claim 16, wherein said anti-sense RNA molecule is directed against hepadnavirus pre-genomic RNA.
19. The DNA construct of claim 18, wherein said hepadnavirus is Hepatitis B virus.
20. The DNA construct of claim 16, wherein said anti-sense RNA is directed against a cellular RNA
species.
species.
21. The DNA construct of claim 1, wherein said third DNA segment comprising said second DNA
segment is replicated to a copy number of at least 100,000 RNA molecules.
segment is replicated to a copy number of at least 100,000 RNA molecules.
22. A method of suppressing Hepatitis B
virus in carriers thereof, said method comprising administering to said carriers the RNA replication products of the DNA construct of claim 11 in such a way as to generate a high copy number of said ribozyme directed against RNA species of said Hepatitis B
virus.
virus in carriers thereof, said method comprising administering to said carriers the RNA replication products of the DNA construct of claim 11 in such a way as to generate a high copy number of said ribozyme directed against RNA species of said Hepatitis B
virus.
23. A method of providing selected anti-sense RNA therapy to patients, said method comprising administering to said patients the RNA
replication products of the DNA construct of claim 16 in such a way as to generate a high copy number of said anti-sense RNA directed against a selected RNA
species.
replication products of the DNA construct of claim 16 in such a way as to generate a high copy number of said anti-sense RNA directed against a selected RNA
species.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60213590A | 1990-10-22 | 1990-10-22 | |
| US602,135 | 1990-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2094608A1 true CA2094608A1 (en) | 1992-04-23 |
Family
ID=24410108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002094608A Abandoned CA2094608A1 (en) | 1990-10-22 | 1991-10-22 | Dna construct for providing rna therapy |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0554376A4 (en) |
| JP (1) | JPH06502311A (en) |
| AU (1) | AU662304B2 (en) |
| CA (1) | CA2094608A1 (en) |
| WO (1) | WO1992006693A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE4203441C1 (en) * | 1992-02-06 | 1993-10-14 | Max Planck Gesellschaft | RNA and DNA molecules to create virus resistance |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| AU687736B2 (en) * | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| US6258585B1 (en) | 1992-05-14 | 2001-07-10 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting influenza virus replication |
| US5804683A (en) * | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| US6017756A (en) * | 1992-05-14 | 2000-01-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting hepatitis B virus replication |
| US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| US5972699A (en) | 1992-05-14 | 1999-10-26 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting herpes simplex virus replication |
| US5891684A (en) * | 1992-10-15 | 1999-04-06 | Ribozyme Pharmaceuticals, Inc. | Base-modified enzymatic nucleic acid |
| AU686614B2 (en) * | 1993-04-05 | 1998-02-12 | Targetech, Inc | Targeted delivery of genes encoding antisense polyribonucleotides |
| AU7053894A (en) * | 1993-06-09 | 1995-01-03 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
| JPH09505461A (en) * | 1993-07-22 | 1997-06-03 | ジーン シェアーズ プロプライアタリー リミティド | DNA virus ribozyme |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JPH09504701A (en) | 1993-11-08 | 1997-05-13 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | Enzymatic nucleic acid with modified base |
| MX9703187A (en) | 1994-11-02 | 1998-02-28 | Trophix Pharm Inc | Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof. |
| US5856459A (en) * | 1995-06-06 | 1999-01-05 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CA2266656A1 (en) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| CA2286304C (en) | 1997-04-10 | 2007-08-07 | Diagnocure Inc. | Pca3, pca3 genes, and methods of use |
| DE69838584T2 (en) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE |
| NZ512122A (en) | 1998-11-27 | 2003-12-19 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
| US6911429B2 (en) | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| AU2001275191A1 (en) | 2000-05-31 | 2001-12-11 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
| EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| US7691821B2 (en) | 2001-09-19 | 2010-04-06 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
| US20020165192A1 (en) | 2000-09-19 | 2002-11-07 | Kerr William G. | Control of NK cell function and survival by modulation of ship activity |
| JP4353701B2 (en) | 2001-05-08 | 2009-10-28 | ダーウィン モレキュラー コーポレイション | Method for regulating immune function in primates using FOXP3 protein |
| AU2002365223A1 (en) | 2001-10-26 | 2003-09-02 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| CN1257284C (en) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | Method of blocking expression of hepatitis B virus |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7807646B1 (en) | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
| US7763592B1 (en) | 2003-11-20 | 2010-07-27 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
| SG185465A1 (en) | 2010-05-14 | 2012-12-28 | Amgen Inc | High concentration antibody formulations |
| EA201391248A1 (en) | 2011-03-01 | 2014-05-30 | Эмджен Инк. | BISPECIFIC BINDING AGENTS |
| CR20160147A (en) | 2011-03-25 | 2016-08-03 | Amgen Inc | FORMULATIONS OF ANTIBODIES |
| EP2739311B9 (en) | 2011-08-04 | 2018-09-19 | Amgen Inc. | Method for treating bone gap defects |
| KR20200056473A (en) | 2011-12-28 | 2020-05-22 | 암젠 인크 | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| CA2953917C (en) | 2013-07-01 | 2021-10-19 | The Research Foundation For The State University Of New York | Ship inhibition to combat obesity |
| WO2015195812A1 (en) | 2014-06-17 | 2015-12-23 | The Research Foundation For The State University Of New York | Ship inhibition to induce activation of natural killer cells |
| MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CA3093457A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4942125A (en) * | 1984-09-07 | 1990-07-17 | Scripps Clinic And Research Foundation | SV40 expression vector containing HBxAg as an expression marker |
| US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
-
1991
- 1991-10-22 AU AU89575/91A patent/AU662304B2/en not_active Ceased
- 1991-10-22 CA CA002094608A patent/CA2094608A1/en not_active Abandoned
- 1991-10-22 EP EP9191920437A patent/EP0554376A4/en not_active Withdrawn
- 1991-10-22 JP JP4500794A patent/JPH06502311A/en active Pending
- 1991-10-22 WO PCT/US1991/007859 patent/WO1992006693A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0554376A4 (en) | 1994-08-24 |
| JPH06502311A (en) | 1994-03-17 |
| EP0554376A1 (en) | 1993-08-11 |
| AU8957591A (en) | 1992-05-20 |
| AU662304B2 (en) | 1995-08-31 |
| WO1992006693A1 (en) | 1992-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU662304B2 (en) | DNA construct for providing RNA therapy | |
| US5225347A (en) | Therapeutic ribozyme compositions and expression vectors | |
| JP4062365B2 (en) | Short external guide arrangement | |
| AU702373B2 (en) | Stabilized external guide sequences | |
| Christoffersen et al. | Ribozymes as human therapeutic agents | |
| US6107028A (en) | Ribozymes for treating hepatitis C | |
| US5610050A (en) | Methods of preventing viral replication | |
| Macejak et al. | Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo | |
| JP2000506010A (en) | Hepatitis C virus ribozyme | |
| Weinberg et al. | Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells | |
| US20040054156A1 (en) | Method and reagent for inhibiting hepatitis B viral replication | |
| Wang et al. | Identification of the functional regions required for hepatitis D virus replication and transcription by linker-scanning mutagenesis of viral genome | |
| Hsieh et al. | Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection | |
| Elkins et al. | Cellular delivery of ribozymes | |
| JPH09507062A (en) | Anti-hepatitis B virus oligonucleotide | |
| MAEDA et al. | Inhibition of viral multiplication by hammerhead ribozymes targeted against the polymerase gene of mouse hepatitis virus | |
| Weinberg | Inhibiting Hepatitis B Virus Gene Expression with Hammerhead Ribozymes that Target the HBx Open Reading Frame | |
| Netter et al. | Hepatitis delta virus | |
| WO2003093473A1 (en) | A multimeric self-cleaving ribozyme construct | |
| WO1998030708A1 (en) | Sv40 viral vectors for targeted integration into cells | |
| WO1998048842A1 (en) | Use of a modified baculovirus containing exogenous nucleic acid for the manufacture of a medicament for delivering said nucleic acid to the hepatocytes | |
| ZA200408825B (en) | A multimeric self-cleaving ribozyme construct. | |
| WO2000014252A1 (en) | Prodrug ribozyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |